That makes Yeztugo a valuable and far more convenient tool for addressing an epidemic that led to around 1.3 million new infections and contributed to the deaths of 630,000 people globally in 2023 ...

That's a less frequent dosage than for all existing HIV prevention medications, including daily pills from Gilead and another injection, from GSK, taken every other month.

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV—a milestone in the decadeslong fight against a once ...

LINKÖPING, Sweden and MISSISSAUGA, ON, June 16, 2025 /PRNewswire/ -- William Osler Health System (Osler) in Canada leverages AI through the international medical imaging IT and cybersecurity ...

Show plans The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

New York City became the first city in the country to allow supervised drug use sites where people can use illegal drugs without threat of arrest, under the watch of trained staff, Mayor Bill de ...

In one late-stage trial, 99.9% of patients who took Gilead's injection did not contract an infection. There were only two cases among more than 2,000 patients, effectively reducing the risk of HIV ...